儿童医院门诊益生菌制剂使用情况的调查分析  

A research and analysis on the application of probiotic preparations in Children's Hospital Outpatient units

作　　者：陈玉梅[1] 程茜[1] 谷容[1] 

机构地区：[1]重庆医科大学附属儿童医院,重庆400014

出　　处：《中国微生态学杂志》2010年第11期1017-1020,共4页Chinese Journal of Microecology

摘　　要：目的了解儿科临床益生菌制剂使用现状及存在问题,为儿科医生合理使用益生菌制剂提供帮助。方法抽取重庆医科大学附属儿童医院2009年1月至12月门诊处方1627024张,并将2月、10月含益生菌制剂的处方9173张按临床诊断进行分类,统计益生菌制剂使用情况,使用制剂,用药年龄,用药科室及疾病,益生菌制剂间的联用及与抗生素联用。结果 1627024张门诊处方中含益生菌制剂处方为54950张,占总处方数的3.38%。54950张含益生菌制剂处方中,含双歧杆菌四联活菌片的处方最多,为19052张,占34.67%(19052/54950);用药患者年龄≤1岁的处方43163张,占78.33%(43163/54950);来自感染消化科的处方31048张,占56.50%(31048/54950);2种益生菌制剂合用的处方765张,占1.39%(765/54950);与抗生素联用的处方13641张,占24.82%(13641/54950)。2月、10月共9173张含益生菌制剂处方中,用于消化道疾病5717张,占62.32%(5717/9173);呼吸系统疾病2389张,占26.04%(2389/5717);新生儿黄疸541张,占5.90%(541/5717);过敏性疾病525张,占5.72%(525/5717)。结论儿科门诊常用双歧杆菌为主成分的益生菌制剂,主要治疗肠道疾病,1岁以下婴儿为主要施治对象,符合微生态制剂药理机制;医生对微生态制剂的成分和耐药益生菌情况不够清楚,造成益生菌制剂与抗生素联用较普遍,并存在组成菌相同或类似的益生菌制剂联用。Objective To study the application situation of probiotic preparations in pediatrics and provide assistance for their reasonable application. Method 1,627,024 pieces of prescriptions were chosen in Children＇s Hospital of Chongqing Medical University from January to December 2009, and 9,173 pieces of prescriptions containing probioties in both February and October were classified according to clinical diagnoses. The use of probiotie preparations, age, department, disease, and combined use of different probiotics and with antibiotics were analyzed. Result There were 54,950 pieces of prescriptions containing probioties. Acepimtomg for 3.38% （54,950/1,627,024）. Of the 54,950 prescriptions, quadruple Live Combined Bifidobacterium was the most frequently prescribed, accounting for 34.67% ; 43,163 pieces （78.33%） were prescribed to babies younger than 1 year old; The prescriptions from Gastroenterology department were 31,048 pieces （56.50%）. There were only 765 （1.39%） prescriptions containing more than two probiotics, while 13,641 （24.82%） pieces had combined probioties. Among the 9,173 pieces of prescriptions in February and October, 3,015 pieces were for gastrointestinal diseases, accounting for 62.32% （5717/9173） ; 2,389 pieces （26.04%） were for respiratory diseases; 541 pieces （5.90%） were for neonatal jaundice; 525 pieces （5.72%） were for anaphylactie diseas- ess. Conclusion In pediatric outpatient clinic, Bifidobacterium preparations axe the probioties commonly used for treatment of intestinal diseases, with infants under 1 year old being the main target population. This is in accordance with the pharmacological mechanism of probiotics. Insufficient knowledge on the microecological agent ingredients and resistant probiotics has lead to more common use of probiotics combined with antibiotics, as well as the combined use of probiotics with similar or even the same ingredients.

关 键 词：益生菌制剂 儿科 使用现状 

分 类 号：R378[医药卫生—病原生物学]